Skip to main content

Table 4 The proportion of participants at month 12 who felt they liked the study procedures and clinical services, by study arm (n = 134)

From: Using surrogate vaccines to assess feasibility and acceptability of future HIV vaccine trials in men: a randomised trial in inner-city Johannesburg, South Africa

Item Immediate vaccination
(n = 68) n liked or very liked (%)
Deferred vaccination
(n = 66) n liked or very liked (%)
P
Study procedures
 Informed consent 56 (82.4) 61 (92.4) 0.080
 Randomisation 61 (89.7) 43 (65.2) 0.001
 Completing questionnaires 62 (92.5) 61 (92.4) 0.980
 Physical examination 60 (88.2) 56 (84.9) 0.565
 Genital examination 59 (86.8) 55 (83.3) 0.436
 Collection of blood samples 58 (85.3) 58 (87.9) 0.661
 Repeated HIV testing 68 (100.0) 63 (95.5) 0.075
 Collection of genital samples 59 (86.8) 58 (87.9) 0.846
 Reimbursement 64 (94.1) 65 (98.5) 0.182
 Other study activitiesa 53 (91.4) 52 (91.2) 0.977
Clinical services
 Visit schedules 64 (86.4) 57 (94.1) 0.129
 Travel time to clinic 54 (79.4) 55 (83.3) 0.560
 Clean clinic environment 68 (100.0) 65 (98.5) 0.308
 Waiting time at clinic 67 (98.5) 62 (93.9) 0.161
 Clinic staff attitude 68 (100.0) 65 (98.5) 0.308
 Examination by female nurse 48 (70.6) 51 (77.3) 0.379
 Examination by male nurse 68 (100.0) 63 (95.5) 0.075
 Free treatment and condoms 67 (98.5) 64 (97.0) 0.542
 Free counselling, health information 68 (100.0) 64 (98.5) 0.305
 Hepatitis B vaccinationb 61 (91.0) - -
  1. aOther activities included in-depth interviews, focus group discussions and home visits’; bonly for those who received the surrogate vaccine; †chi-square test used to calculate P value